Navigation Links
Ranbaxy Gains Approval to Manufacture and Market Cefuroxime Axetil for Oral Suspension
Date:2/6/2008

Ranbaxy to Offer Both Suspension and Tablets

PRINCETON, N.J., Feb. 6 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received approval from the U.S. Food and Drug Administration to manufacture and market Cefuroxime Axetil for Oral Suspension USP, 125 mg/5mL and 250 mg/5mL. The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Ceftin(R) by GlaxoSmithKline. Total annual market sales for Cefuroxime Axetil Suspension were $28.7 million (IMS - MAT: December 2007).

Cefuroxime Axetil Suspension is indicated for the treatment of pediatric patients 3 months to 12 years of age with mild to moderate infections caused by susceptible strains of the designated microorganisms in the following conditions: Pharyngitis/Tonsillitis, Acute Bacterial Otitis Media and Impetigo.

"Ranbaxy is pleased to receive this approval for Cefuroxime Axetil Suspension that now allows us to offer both dosage forms for a product that is highly prescribed. We will offer Cefuroxime Axetil Suspension as a pleasant tasting liquid intended primarily for children that will ease in the acceptance and administration of this anti-infective. This product will further expand our product portfolio of affordable generic alternatives and will be launched immediately to all classes of trade," said Jim Meehan, Vice President of Sales and Distribution for RPI.

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.

Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research
'/>"/>

SOURCE Ranbaxy Laboratories Limited
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine news :

1. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Tablets (OTC), 5mg and 10mg
2. Ranbaxy Receives Tentative Approval For Valsartan Tablets
3. Ranbaxy First to Gain Approval to Manufacture and Market Clarithromycin for Oral Suspension, USP
4. Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market
5. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
6. Shareholder Class Action Filed Against American Dental Partners, Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
7. Medicare Cuts in Bush Budget Shortsighted, Far Off the Mark in Protecting Seniors Long Term Care Needs, Sustaining Nursing Home Quality Gains
8. Hispanic Radio Listeners Nationwide to Support Life-Saving Efforts Against Childhood Cancer
9. Movement Against Cancer, a Cancer Patient Advocacy Group in Russia, Launches an Effort to Inform Russian Authorities and the Public About Inadequate Access of Innovative and Effective Cancer Treatments for Cancer Patients in Russia
10. National Health Care Alliance Gains New Members Against Aetnas New Anesthesia Policy
11. Obesity Action Coalition Calls on the State of Mississippi House of Representatives to Withdraw House Bill 282 Discriminating Against Those Affected by Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Dynatronics Receives 180-Day NASDAQ Extension 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3ERKs got rhythm 3A Protein that controls cell growth found to cycle in and out of cell nucleus 10934 1ERKs got rhythm 3A Protein that controls cell growth found to cycle in and out of cell nucleus 10934 2ERKs got rhythm 3A Protein that controls cell growth found to cycle in and out of cell nucleus 10934 3ERKs got rhythm 3A Protein that controls cell growth found to cycle in and out of cell nucleus 10934 4Tepnel Pharmaceutical Services to Offer DNA Genotek 26apos 3Bs Sample Collection Kit in its Nucleic Acid Extraction and Genotyping Service 15012 1Tepnel Pharmaceutical Services to Offer DNA Genotek 26apos 3Bs Sample Collection Kit in its Nucleic Acid Extraction and Genotyping Service 15012 2Tepnel Pharmaceutical Services to Offer DNA Genotek 26apos 3Bs Sample Collection Kit in its Nucleic Acid Extraction and Genotyping Service 15012 3Ageing Demographic Boosts Uptake of Wireless Patient Monitoring Devices Across Europe Finds Frost 26amp 3B Sullivan 62334 1Ageing Demographic Boosts Uptake of Wireless Patient Monitoring Devices Across Europe Finds Frost 26amp 3B Sullivan 62334 2Ageing Demographic Boosts Uptake of Wireless Patient Monitoring Devices Across Europe Finds Frost 26amp 3B Sullivan 62334 3
Other Medicine Technology:Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 2Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 3Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 4Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 2Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 3Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 4Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 5Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 6Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 7Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 8Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 9